Circulating Markers of Necroptosis in Acute Pancreatitis
Digestive Diseases and Sciences · 2024
DOI: 10.1007/s10620-024-08530-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Hanna Belfrage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland. hanna.belfrage@hus.fi. Hauptthemen laut MEDLINE: Necroptosis, Biomarkers, Pancreatitis, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Finska läkarsällskapet, Helsinki university hospital, Univerisity of Helsinki, The Mary and Georg Ehrnrooth Foundation.
Abstract (Originalsprache)
OBJECTIVES: Necroptosis, a programmed inflammatory cell death, is involved in the pathogenesis of acute pancreatitis (AP). We compared levels of interleukin (IL)-33 (released upon necroptosis), sST2 (soluble IL-33 receptor), MLKL, RIPK1 and RIPK3 (necroptosis executioner proteins), and proinflammatory cytokines IL-6, TNF and IL-1β at various severity categories and stages of AP. METHODS: Plasma from 20 patients with early mild AP (MAP) (symptom onset < 72 h), 7 with severe AP (SAP) without and 4 with persistent organ failure (OF) at sampling, 8 patients with late SAP and 20 healthy controls (HC) were studied by ELISAs. RESULTS: Early sST2 and IL-6 levels predicted the development of SAP and were higher in both MAP and early and late SAP than in HC. RIPK3 levels were higher than in HC in the patients who had or would later have SAP. MLKL levels were associated with the presence of OFs, particularly in the late phase, but were also higher in MAP than in HC. CONCLUSIONS: sST2, RIPK3 and IL-6 levels may have prognostic value in AP. Elevated MLKL levels are associated with OF in AP. Better understanding of necroptosis in AP pathophysiology is needed to evaluate whether inhibiting and targeting necroptosis is a potential therapeutic option in AP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland. hanna.belfrage@hus.fi.
- Department of Bacteriology and Immunology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Department of Surgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland.
Förderung
- Finska läkarsällskapet
- Helsinki university hospital, Univerisity of Helsinki
- The Mary and Georg Ehrnrooth Foundation
- University of Helsinki
Zitieren
APA
Belfrage, H., Kuuliala, K., Kuuliala, A., Mustonen, H., Puolakkainen, P., Kylänpää, L., & Louhimo, J. (2024). Circulating Markers of Necroptosis in Acute Pancreatitis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08530-6
Vancouver
Belfrage H, Kuuliala K, Kuuliala A, Mustonen H, Puolakkainen P, Kylänpää L, et al. Circulating Markers of Necroptosis in Acute Pancreatitis. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08530-6
BibTeX
@article{Belfrage2024,
author = {Belfrage, Hanna and Kuuliala, Krista and Kuuliala, Antti and Mustonen, Harri and Puolakkainen, Pauli and Kylänpää, Leena and Louhimo, Johanna},
title = {Circulating Markers of Necroptosis in Acute Pancreatitis},
journal = {Digestive Diseases and Sciences},
year = {2024},
doi = {10.1007/s10620-024-08530-6}
}
EUVIMED